Alterity Therapeutics Limited (ATHE)

CIK 0001131343 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —
FY-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
—
Document and Entity Information
—
Audit Information
—
Statements
Consolidated Statements of Financial Position
—
Consolidated Statements of Financial Position (P)
—
Consolidated Statements of Profit Or Loss and Other Comprehensive Loss
—
Consolidated Statements of Profit Or Loss and Other Comprehensive Loss (P)
—
Consolidated Cash Flow Statements
—
Consolidated Statements of Changes In Shareholders' Equity
—
Notes
Accumulated Deficit During Development Stage
—
Auditors' Remuneration
—
Background and Summary of Material Accounting Policies
—
Background and Summary of Significant Accounting Policies
—
Cash Flow Information
—
Commitments and Contingencies
—
Cybersecurity Risk Management and Strategy Disclosure
—
Expenditure Commitments
—
Expenses From Ordinary Activities
—
Financial Instruments
—
Income Tax
—
Insider Trading Policies and Procedures
—
Interest and Other Income From Continuing Operations
—
Issued Capital
—
Key Management Personnel Compensation
—
Leases
—
Loss Per Share
—
Other Current Assets
—
Parent Entity Financial Information
—
Provisions
—
Related Party Transactions
—
Reserves
—
Segment Information
—
Share Based Payments
—
Subsequent Events
—
Trade and Other Payables
—
Trade and Other Receivables
—